Sunfox Technologies
Developer of Spandan, a portable, smartphone-connected 12-lead ECG platform for accessible cardiac assessment.
Website: https://www.sunfox.in/
Cover Block
Open sources
| Field | Detail |
|---|---|
| Company | Sunfox Technologies |
| Tagline | Developer of Spandan, a portable, smartphone-connected 12-lead ECG platform for accessible cardiac assessment [Sunfox Technologies] |
| Headquarters | Dehradun, India [VCCircle] |
| Founded | 2016 [VCCircle] |
| Stage | Series A [Economic Times - ET Entrepreneur, October 2026] |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | Hardware |
| Geography | South Asia |
| Growth profile | Venture Scale |
| Founding team | Rajat Jain, Arpit Jain, Sabit Rawat, Nitin Chandola, Saurabh Badola [VCCircle] |
| Funding label | Series A |
| Total disclosed funding | Approximately $7,000,000 [Economic Times - ET Entrepreneur, October 2026] |
Links
Open sources
- Website: https://www.sunfox.in/
- LinkedIn: https://in.linkedin.com/company/sunfox
What an Investor Needs First
PUBLIC Sunfox Technologies builds Spandan, a portable, smartphone-connected ECG platform, and it merits investor attention now because it has paired a relatively clear clinical use case with fresh Series A capital and a reported national deployment footprint in India [Economic Times - ET Entrepreneur, October 2026] [Sunfox Technologies] [VCCircle]. Founded in Dehradun in 2016 by Rajat Jain, Arpit Jain, Sabit Rawat, Nitin Chandola, and Saurabh Badola, the company traces its origin, according to coverage, to the founders’ response to the loss of a friend and a desire to shorten the time to cardiac assessment after a heart event [VCCircle] [Economic Times - ET Entrepreneur, October 2026]. The product case rests on portability rather than novelty for its own sake: Sunfox says Spandan delivers a 12-lead assessment from a smartphone-connected device, while published and indexed clinical studies cited in public sources report that Spandan Pro showed comparable accuracy to standard 12-lead ECG for ST-elevation decision support in PCI-related contexts [Sunfox Technologies] [ThePrint, August 2024] [PubMed] [PMC].
The team picture is unusually broad for a medtech startup of this size, with Rajat Jain publicly identified as CEO and Arpit Jain, Nitin Chandola, Saurabh Badola, and Sabit Rawat tied to product, hardware, software, and commercial roles across company and profile sources, although the public record is uneven on each founder’s prior operating history outside Sunfox [LinkedIn] [IndiaMart] [ZoomInfo] [VCCircle]. On financing, the company has moved from an early 2022 equity round associated with Namita Thapar and other prominent angel investors to SAMRIDH support in 2023, a Venture Catalysts-led pre-Series round in 2024, and a $7 million Series A in October 2026 backed by Ashish Kacholia, Lashit Sanghvi, Alchemy Capital, and 3one4 Capital, suggesting sustained investor appetite across angel, programmatic, and institutional pools [Whiteford Research company profile] [SAMRIDH] [ThePrint, August 2024] [Economic Times - ET Entrepreneur, October 2026]. The business model appears to be hardware plus software, with Sunfox marketing Spandan across home monitoring, clinics, hospitals, telemedicine, and public-health settings, and also listing device variants and consumables that could support recurring revenue beyond initial device sales [Sunfox Technologies] [YourStory, October 2026]. Public traction claims are directionally encouraging but still need careful parsing: multiple outlets report roughly 60,000 devices deployed across India and reach into more than 20,000 villages, yet user, clinical outcome, and commercial quality metrics remain mostly company-supplied or thinly corroborated in public [Economic Times - ET Entrepreneur, October 2026] [CXO Digitalpulse] [Newskart].
Over the next 12 to 18 months, the central questions are whether Sunfox can convert deployment breadth into repeatable institutional revenue, deepen clinical evidence beyond narrow study settings, and execute on international expansion without diluting the operational focus that has underpinned its India footprint so far [Economic Times - ET Entrepreneur, October 2026] [Entrackr, October 2026] [YourStory, October 2026].
Partially corroborated -- This section relies on a mix of independent press coverage, company materials, and profile databases; core facts on founding, financing, and broad deployment are corroborated, while several product and traction details remain partly company-sourced.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Hardware |
| Geography | South Asia |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Total disclosed approximately $7,000,000 |
Inside the Company
PUBLIC Sunfox Technologies is a Dehradun-based Indian medtech company founded in 2016, with a plain but consequential thesis: make 12-lead cardiac assessment portable enough to move beyond tertiary care settings and into everyday clinical, frontline, and remote use [Sunfox Technologies]. The company is best known for Spandan, a smartphone-connected ECG platform positioned for personal, clinical, hospital, telemedicine, and public-health workflows [Sunfox Technologies].
Public company materials present Sunfox as the developer of a portable ECG system built for accessibility and mobility rather than fixed-site diagnostics [Sunfox Technologies]. The company’s public footprint also shows an active hiring posture in product design, with its careers page listing a Product UX Designer role at the time of retrieval, a small but useful signal that the software layer remains part of the buildout alongside the device business [Sunfox Technologies].
The chronology that can be established from the permitted sources is narrow but usable. Sunfox dates its founding to 2016 and, by its own product and careers pages, is operating as an ongoing commercial entity around the Spandan platform [Sunfox Technologies]. Within those bounds, the company reads less like a single-device project and more like an attempt to build a broader cardiac diagnostics stack anchored by portable hardware and companion software [Sunfox Technologies].
Claim stands unchecked -- This section relies primarily on company website materials, with no Crunchbase or state-filing corroboration used in this section.
Under the Hood
Reported and inferred
Sunfox’s product case rests on a simple claim that is easier to verify than many digital health pitches: Spandan is a portable ECG platform that connects to a smartphone and is built to bring cardiac assessment closer to the point of first contact, whether that is a clinic, a hospital, a telemedicine workflow, or a frontline health setting [Sunfox Technologies]; [VCCircle]; [YourStory, October 2026]. Public materials and press coverage describe it as a 12-lead cardiac assessment system, with ThePrint reporting that the device can generate clinically accurate 12-lead readings and help identify suspected heart attacks through a smartphone-connected workflow [ThePrint, August 2024]. Sunfox’s site also says the ECG can be completed sequentially in under two minutes and identifies product variants including Spandan Ultra 12L, Spandan Pro, and disposable electrodes, although those SKU-level claims remain company-sourced rather than independently corroborated [Sunfox Technologies].
The strongest public evidence sits not in marketing copy but in clinical validation references tied to Spandan Pro. A published observational study available via PMC, PubMed, and Cardiology Research reported that Spandan Pro ECG, described there as a single-channel autoswitched ECG machine, showed comparable accuracy to a standard 12-lead ECG for diagnosing ST elevation and supported decision-making for patients requiring PCI [PMC]; [PubMed]; [Cardiology Research]. A separate evaluation on PMC reported perfect concordance between Spandan Pro and the gold-standard method for PCI recommendations, which is notable, although readers should treat that as evidence for a specific clinical use case rather than blanket proof across all care settings [PMC]. On the software side, the only defensible inference from currently surfaced hiring is that user experience design for both web and native mobile applications remains an active priority, based on the company’s Product UX Designer opening requiring experience across iOS, Android, and complex web products (inferred from job postings) [Sunfox Technologies Careers].
Partially corroborated -- Product form factor and use cases are corroborated by company materials and press coverage, while the strongest performance claims rely on published validation studies and several feature details remain company-only.
Market Research
PUBLIC
Portable cardiac diagnostics matter now because the pressure points are obvious: cardiovascular disease needs earlier detection, but a full 12 lead ECG has historically been tied to clinics, trained operators, and stationary equipment, while Sunfox is positioning Spandan against that access gap rather than against a narrow device niche [Sunfox Technologies]; [VCCircle].
The research packet does not include a third-party TAM, SAM, or SOM study specific to portable ECG in India, so any market sizing here has to stay narrow and source-bound. What is visible in public sources is the addressable use environment. Sunfox and external coverage consistently place Spandan across hospitals, clinics, telemedicine networks, public-health systems, frontline health workers, and home monitoring, which implies exposure to several adjacent budgets rather than a single procurement motion [VCCircle]; [YourStory, October 2026]; [Sunfox Technologies]. That matters because the company is not selling into one monolithic medtech market. It is touching point-of-care diagnostics, remote monitoring, public-health deployment, and physician workflow software, each with different buying cycles and evidence standards.
The closest public signal of realized demand is not a market report but deployment breadth. Coverage in October 2026 said approximately 60,000 Spandan devices had been deployed across India and had reached more than 20,000 villages, figures that were repeated by multiple outlets and attributed to the company [Economic Times - ET Entrepreneur, October 2026]; [Entrackr, October 2026]; [CXO Digitalpulse]; [Newskart]. Those numbers do not establish market size, but they do suggest that portable ECG has moved beyond pilot status in at least some Indian frontline settings.
| Cited market proxy | Figure | Why it matters |
|---|---|---|
| Spandan devices deployed across India | 60,000 | Indicates field penetration in the target use case for portable ECG [Economic Times - ET Entrepreneur, October 2026]; [CXO Digitalpulse] |
| Villages reached in India | 20,000+ | Suggests rural and distributed-care applicability, not only urban clinical use [Economic Times - ET Entrepreneur, October 2026]; [Newskart] |
| Users claimed by company | 30,000+ in 20 countries | Shows international ambition, but remains company-reported rather than independently verified [Sunfox Technologies, August 2024] |
The practical takeaway is that the available evidence supports a broad use-case market with demonstrated field adoption, but not a clean top-down market model. Investors should read the opportunity less as "India ECG hardware" and more as a distributed cardiac assessment layer that can sit inside public health, clinic digitization, and telecardiology workflows, assuming procurement and clinical validation continue to hold.
Demand tailwinds in the source set are mostly structural. The first is care decentralization: SAMRIDH said its support was used for technical and sales-team strengthening and for deployment of Spandan in public-health facilities in tier-2 and tier-3 cities, which is a direct indicator that lower-cost, portable diagnostics fit state and quasi-public delivery models outside major urban hospitals [SAMRIDH]. The second is smartphone-linked workflow. Sunfox describes Spandan as smartphone-connected and usable across personal, clinical, hospital, telemedicine, and public-health settings, while ThePrint said the device can generate 12 lead readings and help identify suspected heart attacks using a smartphone [Sunfox Technologies]; [ThePrint, August 2024]. In plain terms, the category benefits when diagnostics can be captured near the patient and escalated remotely.
Clinical evidence, while still limited in scope, is another tailwind for the category. A published observational study indexed on PubMed and mirrored on PMC and Cardiology Research reported that Spandan Pro ECG showed comparable accuracy to a gold-standard 12 lead ECG for diagnosis of ST elevation in the study context, and helped support PCI decision-making [PubMed]; [PMC]; [Cardiology Research]. A separate PMC-cited evaluation reported perfect concordance with PCI recommendations in its testing framework [PMC]. That does not settle broad commercial adoption, but it does matter for market formation because portable ECG hardware in regulated care settings tends to win or lose on whether clinicians trust the output enough to incorporate it into decision support.
The adjacent markets are as important as the core one. Sunfox is showing up at the intersection of at least four categories: diagnostic hardware, telemedicine infrastructure, remote patient monitoring, and public-health screening [VCCircle]; [YourStory, October 2026]; [Sunfox Technologies]. The substitute set is broad as well, even if named competitors were not surfaced in the research. Traditional 12 lead ECG systems remain the clinical benchmark referenced in the validation studies, while single-purpose monitoring tools and telehealth-first workflows can substitute in some lower-acuity scenarios depending on care setting and reimbursement logic [PubMed]; [PMC]. That creates a market dynamic where winning does not require replacing incumbent hospital machines outright. It may instead depend on expanding the number of moments when an ECG is captured at all.
Regulatory and macro forces in the packet are indirect but still relevant. The strongest public signal is institutional support from USAID through SAMRIDH Health, which backed deployment in public-health facilities and team expansion, implying that portable cardiac diagnostics fit broader health-access and system-capacity agendas [SAMRIDH]; [Sunfox Technologies, August 2024]. The 2026 Series A coverage also said proceeds would go toward Indian expansion, international go-to-market development, R&D, clinical evidence, engineering, and new cardiac technologies, which suggests the category increasingly rewards companies that can pair hardware distribution with evidence generation and compliance-oriented scaling rather than relying on consumer electronics economics alone [Economic Times - ET Entrepreneur, October 2026]; [YourStory, October 2026].
The constraint is that the public record here is still lighter on formal market studies than on company deployment anecdotes. That does not weaken the underlying need state. It does mean the market case currently rests more on visible adoption in distributed-care settings and on early clinical validation than on a fully documented third-party market map.
Partially corroborated -- Section relies on multiple public sources for deployment context and use-case breadth, but lacks third-party market sizing studies and includes some company-attributed claims.
Competition and Substitutes
Current positioning
MIXED Sunfox sits in the portable cardiac diagnostics lane, positioned closer to point-of-care ECG access than to full-stack hospital cardiology infrastructure, according to its public product materials and funding coverage [Sunfox Technologies] [Economic Times - ET Entrepreneur, October 2026].
The public record here is narrower than usual, and that matters. On the evidence available, the practical substitutes break into three groups: conventional 12-lead ECG systems used in hospitals and clinics, telemedicine workflows that depend on referral or facility-based diagnostics, and frontline screening pathways that may rely on delayed access rather than immediate ECG capture [Sunfox Technologies] [VCCircle].
That framing puts Sunfox in a useful middle position. Spandan is described as a portable, smartphone-connected 12-lead ECG platform, and outside coverage has repeated the claim that it can produce clinically accurate 12-lead readings and support suspected heart attack identification through a smartphone workflow [Sunfox Technologies] [ThePrint, August 2024]. If that product claim holds across real-world settings, the company competes less on feature breadth than on whether it can bring cardiology-grade signal capture into settings where a standard machine, trained operator, or specialist is not immediately available [ThePrint, August 2024] [YourStory, October 2026].
The strongest visible edge today is distribution footprint, though the durability of that edge is still open to question. By October 2026, reported deployment had reached around 60,000 devices across India and more than 20,000 villages, figures cited by Economic Times and echoed in other public coverage [Economic Times - ET Entrepreneur, October 2026] [Entrackr, October 2026]. That suggests Sunfox has moved beyond prototype-stage market discovery and into a broader field presence. Still, footprint is not the same thing as lock-in. A hardware plus software model can create switching friction once users are trained and workflows are embedded, but the public evidence does not yet establish proprietary data advantages, exclusive channels, or reimbursement moats that would make the position hard to replicate [Sunfox Technologies] [SAMRIDH, March 2023].
The company is also exposed where incumbents usually win: validated clinical relationships, procurement muscle, and integrated care pathways. Publicly cited validation work around Spandan Pro is helpful because it points to comparable accuracy with a gold standard 12-lead ECG for ST-elevation diagnosis in the referenced study context, and to usefulness in PCI decision-making [PubMed] [PMC]. But evidence from a study and evidence of scaled institutional preference are different things. If hospital systems or public-health buyers decide they prefer devices bundled with established service networks, training programs, and long procurement histories, Sunfox could find that product portability alone is not enough to secure the highest-value accounts [PMC] [Cardiology Research] [Economic Times - ET Entrepreneur, October 2026].
Over the next 18 months, the most plausible competitive split is not between Sunfox and a single confirmed rival, but between portable-first ECG platforms and incumbent facility-based diagnostics. In that scenario, Sunfox is the likely winner if public-health programs, clinics, and distributed care networks continue to prioritize reach, lower-friction deployment, and smartphone-linked workflows, especially in tier-2, tier-3, and village settings where SAMRIDH-backed deployment appears to have given the company operating experience [SAMRIDH, March 2023] [Economic Times - ET Entrepreneur, October 2026]. The likely loser, if that shift does not materialize, is Sunfox itself: if purchasing consolidates around entrenched clinical vendors or if buyers treat portable ECGs as supplementary rather than workflow-critical, the company's current advantage looks perishable rather than structural.
Opportunity
PUBLIC
The prize here is not a marginally better ECG device, but a credible shot at becoming one of the default front-door cardiac assessment platforms for distributed care across India and selected export markets, if Sunfox can convert early device reach into durable clinical and channel adoption [Economic Times - ET Entrepreneur, October 2026] [YourStory, October 2026].
The headline opportunity is straightforward. Sunfox is selling into a problem that is structurally hard to solve with legacy hospital-bound hardware: how to get 12-lead cardiac assessment closer to the patient, faster, and at lower operational friction across clinics, telemedicine settings, public-health programs, and home monitoring pathways [Sunfox Technologies] [VCCircle]. What makes the upside more reachable than purely aspirational is that the company is not starting from concept-stage evidence. Public reporting says Spandan devices had been deployed across India at roughly 60,000 units and had reached more than 20,000 villages by October 2026, while the product has also attracted follow-on financing from both ecosystem backers and institutional investors, culminating in a reported $7 million Series A round [Economic Times - ET Entrepreneur, October 2026] [Entrackr, October 2026] [ThePrint, August 2024]. That combination, field distribution plus external capital plus some clinical validation work, is the sort of base from which a category leader can emerge, even if execution risk remains substantial [PMC] [PubMed] [Cardiology Research].
The upside branches into a few distinct growth paths, and the public evidence suggests more than one is open.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Rural cardiac infrastructure layer | Spandan becomes a standard screening and referral tool across frontline care, public-health facilities, and smaller clinics in underserved geographies | Expanded public-health procurement or programmatic deployment through channels similar to SAMRIDH-backed rollouts [SAMRIDH, March 2023] | Sunfox already reported deployment into public-health facilities in tier-2 and tier-3 settings, and public coverage says devices have reached more than 20,000 villages across India [SAMRIDH, March 2023] [Economic Times - ET Entrepreneur, October 2026] |
| Telecardiology distribution winner | Spandan becomes the preferred device layer for telemedicine networks and remote physician interpretation workflows | International go-to-market buildout after the Series A, plus further integration into remote-care pathways [Economic Times - ET Entrepreneur, October 2026] [YourStory, October 2026] | The product is explicitly positioned for telemedicine and remote-care use, and the company says it already has users across 20 countries, though that geography claim remains company-reported [Sunfox Technologies, August 2024] [Sunfox Technologies] |
| Clinical wedge into broader cardiac monitoring | Sunfox uses ECG adoption to expand into a wider cardiac software and device stack for doctors, clinics, and hospitals | Continued R&D and clinical-evidence generation funded by the 2026 round [Economic Times - ET Entrepreneur, October 2026] | The company already markets multiple product variants including Spandan Ultra 12L and Spandan Pro, and published validation studies indicate Spandan Pro showed agreement with gold-standard ECG decision support in PCI-related contexts [Sunfox Technologies] [PMC] [PubMed] [Cardiology Research] |
What compounding looks like is a distribution-and-evidence flywheel rather than a consumer network effect. More devices in the field can create more clinician familiarity, more use across peripheral settings, more data supporting workflow acceptance, and then stronger credibility with hospital administrators, telemedicine operators, and public-health buyers. The public record suggests the first turns of that wheel may already be visible: Sunfox has moved from early angel and programmatic backing to a larger pre-Series financing in 2024 and then a $7 million Series A in 2026, while also accumulating published validation work around PCI decision support and ST-segment agreement for Spandan Pro [ThePrint, August 2024] [Economic Times - ET Entrepreneur, October 2026] [PMC] [PubMed]. In medtech, that matters because each layer of evidence can lower adoption friction for the next channel, especially when the product is meant to be used outside top-tier urban hospital settings.
The size of the win is best framed conditionally because no credible public market-sizing figure is available in the sourced material. If Sunfox were to become a scaled cardiac diagnostics platform with durable placement in Indian frontline care and a repeatable international telecardiology motion, the outcome could support a meaningfully larger enterprise than a device-only business, particularly if software, consumables, and clinical workflow become a larger share of revenue over time. The public evidence does not support a precise valuation analogue, so any number here would be less disciplined than the facts allow. Still, the strategic shape of the upside is clear: a company that starts with portable ECG hardware and proves itself as infrastructure for distributed cardiac assessment can plausibly graduate from product vendor to care-delivery layer, and that is the kind of transition on which outsized medtech returns are usually built [Economic Times - ET Entrepreneur, October 2026] [Sunfox Technologies] [YourStory, October 2026].
Partially corroborated -- This section relies on a mix of independent news coverage, program documentation, and company materials; key deployment and product-positioning claims have partial corroboration, while some international user and use-case breadth claims remain company-reported.
Sources
Open sources
[Sunfox Technologies] Spandan Portable 12-Lead ECG | Sunfox Technologies | https://www.sunfox.in/
[VCCircle] Sunfox Technologies | https://www.vccircle.com/bytexlsunfox-technologies-zomint-others-pocket-early-stage-cheques
[Economic Times - ET Entrepreneur, October 2026] Sunfox Technologies raises $7 mn series A funding | https://entrepreneur.economictimes.indiatimes.com/news/funding/sunfox-technologies-raises-7-mn-series-a-funding/134756483
[ThePrint, August 2024] Sunfox Technologies secures additional Rs 15 crore in pre-Series funding to scale global cardiac innovations | https://theprint.in/ani-press-releases/sunfox-secures-additional-rs-15-crore-in-pre-series-funding-to-scale-global-cardiac-innovations/2243717/
[LinkedIn] Sunfox Technologies | LinkedIn | https://in.linkedin.com/company/sunfox
[Whiteford Research company profile] Sunfox | https://biobase.whitefordresearch.com/companies/sunfox
[SAMRIDH] Sunfox | https://www.samridhimpact.com/sunfox/
[YourStory, October 2026] Medtech company Sunfox Technologies raises $7M to scale cardiac diagnostics platform | https://yourstory.com/2026/10/medtech-company-sunfox-technologies-raises-7m
[Entrackr, October 2026] Med-tech startup Sunfox Technologies raises $7 Mn in Series A round | https://entrackr.com/snippets/med-tech-startup-sunfox-technologies-raises-7-mn-in-series-a-round-12633059
[Bloomberg Markets, retrieved 2026] Rajat Jain, Oriental Carbon & Chemicls Ltd: Profile and Biography - Bloomberg Markets | https://www.bloomberg.com/profile/person/24117207
[ZoomInfo, retrieved 2026] Sunfox Technologies | ZoomInfo | https://www.zoominfo.com/c/sunfox-technologies/539345642
[IndiaMart, retrieved 2026] Sunfox Technologies Pvt Ltd | IndiaMART | https://www.indiamart.com/sunfox-technologies/
[Sunfox Technologies Careers] Careers | Sunfox Technologies | https://www.sunfox.in/careers
[PubMed] Validation of Decisions for Percutaneous Coronary Intervention Using Smartphone-Based Electrocardiogram Device Spandan: A Cross-Sectional Observational Study | https://pubmed.ncbi.nlm.nih.gov/37602125/
[PMC] Validation of Decisions for Percutaneous Coronary Intervention Using Smartphone-Based Electrocardiogram Device Spandan: A Cross-Sectional Observational Study | https://pmc.ncbi.nlm.nih.gov/articles/PMC10461170/
[Cardiology Research] Validation of Decisions for Percutaneous Coronary Intervention Using Smartphone-Based Electrocardiogram Device Spandan: A Cross-Sectional Observational Study | https://cardiologyres.org/index.php/Cardiologyres/article/view/1457
[CXO Digitalpulse] Sunfox Technologies reaches 60,000 device deployment milestone | https://cxodigitalpulse.com/sunfox-technologies-reaches-60000-device-deployment-milestone/
[Newskart] Sunfox Technologies expands Spandan reach across 20,000 villages | https://newskart.com/sunfox-technologies-expands-spandan-reach-across-20000-villages/
Articles about Sunfox Technologies
- Sunfox's 60,000 Smartphone ECGs Are a New Frontline for Heart Attacks — The Indian medtech startup's portable Spandan device, now in 20,000 villages, just secured a $7 million Series A to expand its reach.